Comparative study of Choline Alfoscerate as a combination therapy with donepezil

Seoul National University Hospital0 个研究点目标入组 200 人开始时间: 待定最近更新: 2020年2月24日

研究概览

暂无简介。

•Adult men and women aged 50 to 85
•-A person who can understand and make explanations on their own or can get help from an agent (spouse, first-line immediate family).
•-Those who have been taking stablepezil for more than 3 months with K-MMSE score of 26 or less
•Donepezil alone or in combination with choline alfoscerate selected Acetyl-L-carnitine and Ginkgo biloba
•-Those who agree with the study

•-Allergies or hypersensitivity to test drugs
•-Patients with clinically significant digestive system diseases who refuse nausea or vomiting due to the AchE inhibitor family. (Except those who have been resolved by adjusting the dose)
•-Those who have had surgery or other oral administration that may interfere with food absorption
•-A significant abnormal finding of liver function or renal function was observed on physical examination after this study, or those diagnosed with liver function or renal function abnormality in other organs (However, there is a chronic disease of liver or kidney but it is controlled. Cases shall not be excluded for this reason)
•-Have other major psychiatric disorders
•Patients with unstable physical conditions or diseases that can impede proper evaluation and treatment
•-Alcohol or drug addicts
•-If you participate in other clinical trials besides this clinical trial, you cannot know the effects of other clinical trials and drug interactions.

发起方